May 5 (Reuters) – Swiss drugmaker Novartis said on Tuesday that it is set to cut around 220 jobs in Germany as part of the planned closure of a production site by the end of 2028.
The production site in Wehr, Germany, which manufactures tablets and capsules, is no longer competitive, the Swiss company said in a statement.
The planned site closure is not related to Novartis’ recent ramp-up in investments into U.S. manufacturing following U.S. tariff threats, nor connected to Germany’s new healthcare measures, Novartis told Reuters separately in an email. The company remains committed to Germany as a location, it added.
(Reporting by Marleen Kaesebier and Maggie Fick; editing by Matthias Williams)
